Lev M. Berstein

4.7k total citations
103 papers, 3.6k citations indexed

About

Lev M. Berstein is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Lev M. Berstein has authored 103 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Genetics, 45 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Lev M. Berstein's work include Estrogen and related hormone effects (46 papers), Cancer Risks and Factors (27 papers) and Metabolism, Diabetes, and Cancer (21 papers). Lev M. Berstein is often cited by papers focused on Estrogen and related hormone effects (46 papers), Cancer Risks and Factors (27 papers) and Metabolism, Diabetes, and Cancer (21 papers). Lev M. Berstein collaborates with scholars based in Russia, United States and Netherlands. Lev M. Berstein's co-authors include И. Г. Коваленко, Richard J. Santen, Mark A. Zabezhinski, Irina G. Popovich, Vladimir N. Anisimov, Anna V. Semenchenko, Peter A. Egormin, Tatiana S. Piskunova, Wei Yue and Е. V. Tsyrlina and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lev M. Berstein

96 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lev M. Berstein Russia 33 1.7k 1.1k 1.1k 971 515 103 3.6k
Bonnie J. Deroo United States 20 1.9k 1.1× 1.3k 1.2× 964 0.9× 574 0.6× 216 0.4× 29 3.9k
Stefano Bertolini Italy 35 1.4k 0.8× 519 0.5× 271 0.3× 821 0.8× 719 1.4× 129 4.7k
Giuseppe Pandini Italy 31 3.9k 2.3× 512 0.5× 1.3k 1.2× 1.4k 1.5× 494 1.0× 50 5.7k
Shixia Huang United States 30 2.4k 1.4× 481 0.4× 1.3k 1.3× 651 0.7× 246 0.5× 70 3.7k
Kimberly D. Kluckman United States 15 1.7k 1.0× 771 0.7× 716 0.7× 338 0.3× 396 0.8× 17 4.5k
Hyun‐Seok Kim South Korea 22 1.5k 0.9× 238 0.2× 486 0.5× 414 0.4× 703 1.4× 76 3.4k
Jackie A. Lavigne United States 23 706 0.4× 398 0.4× 465 0.4× 351 0.4× 508 1.0× 28 1.9k
Anders Ström Sweden 36 2.4k 1.4× 2.9k 2.6× 1.5k 1.4× 815 0.8× 187 0.4× 68 5.4k
Lothar Rössig Germany 26 3.1k 1.9× 140 0.1× 825 0.8× 829 0.9× 820 1.6× 39 5.1k
Jack Youngren United States 30 1.4k 0.8× 298 0.3× 353 0.3× 624 0.6× 801 1.6× 70 3.6k

Countries citing papers authored by Lev M. Berstein

Since Specialization
Citations

This map shows the geographic impact of Lev M. Berstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lev M. Berstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lev M. Berstein more than expected).

Fields of papers citing papers by Lev M. Berstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lev M. Berstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lev M. Berstein. The network helps show where Lev M. Berstein may publish in the future.

Co-authorship network of co-authors of Lev M. Berstein

This figure shows the co-authorship network connecting the top 25 collaborators of Lev M. Berstein. A scholar is included among the top collaborators of Lev M. Berstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lev M. Berstein. Lev M. Berstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berstein, Lev M.. (2019). Is cancer incidence modified by SGLT2 inhibitors?. Diabetes Mellitus. 22(4). 399–402.
2.
Belyaev, А. М., et al.. (2018). Diagnostic score of malignancy risk in the people having a node in thyroid gland (Petrov Thyroid Cancer Score, PTCS). Head and neck tumors (HNT). 8(1). 17–23.
3.
Samsonov, R. B., Vladimir Burdakov, Tatiana Shtam, et al.. (2016). Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumor Biology. 37(9). 12011–12021. 95 indexed citations
4.
Berstein, Lev M., et al.. (2011). Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Medical Oncology. 29(2). 1308–1313. 16 indexed citations
5.
Berstein, Lev M., et al.. (2010). More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Medical Oncology. 28(4). 1260–1263. 32 indexed citations
6.
Berstein, Lev M., Wei Yue, Jiping Wang, & Richard J. Santen. (2010). Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Research and Treatment. 128(1). 109–117. 42 indexed citations
7.
Anisimov, Vladimir N., Lev M. Berstein, Peter A. Egormin, et al.. (2008). Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 7(17). 2769–2773. 273 indexed citations
8.
Berstein, Lev M., et al.. (2006). Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes. Maturitas. 54(4). 352–355. 7 indexed citations
9.
Santen, Richard J., Ran Song, Rakesh Kumar, et al.. (2005). Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocrine Related Cancer. 12(Supplement_1). S61–S73. 98 indexed citations
10.
Anisimov, Vladimir N., Lev M. Berstein, Peter A. Egormin, et al.. (2005). Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology. 40(8-9). 685–693. 324 indexed citations
11.
Anisimov, Vladimir N., Lev M. Berstein, Irina G. Popovich, et al.. (2005). Central and Peripheral Effects of Insulin/IGF‐1 Signaling in Aging and Cancer: Antidiabetic Drugs as Geroprotectors and Anticarcinogens. Annals of the New York Academy of Sciences. 1057(1). 220–234. 16 indexed citations
12.
Vf, Semiglazov, Vladimir Semiglazov, В Г Иванов, et al.. (2004). The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. Journal of Clinical Oncology. 22(14_suppl). 519–519. 16 indexed citations
13.
Santen, Richard J., Ran Song, Rakesh Kumar, et al.. (2003). Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.. Endocrine Related Cancer. 10(2). 111–130. 34 indexed citations
14.
Larionov, Alexey A., et al.. (2003). Aromatase in skeletal muscle. The Journal of Steroid Biochemistry and Molecular Biology. 84(4). 485–492. 43 indexed citations
15.
Berstein, Lev M., Evgeny N. Imyanitov, Ekatherina Sh. Kuligina, et al.. (2002). CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?. Cancer Letters. 180(1). 47–53. 35 indexed citations
16.
17.
Jefcoate, Colin R., Joachim G. Liehr, Richard J. Santen, et al.. (2000). Chapter 5: Tissue-Specific Synthesis and Oxidative Metabolism of Estrogens. JNCI Monographs. 2000(27). 95–112. 207 indexed citations
18.
Berstein, Lev M., et al.. (2000). Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy. The Journal of Steroid Biochemistry and Molecular Biology. 72(3-4). 143–147. 27 indexed citations
19.
Berstein, Lev M., et al.. (1998). Influence of tobacco smoke on DNA unwinding and uterotrophic effect of estrogens in rats. Cancer Letters. 127(1-2). 95–98. 3 indexed citations
20.
Pető, Richárd, Basil A. Stoll, Lev M. Berstein, et al.. (1997). Birthweight as risk factor for breast cancer (multiple letters) [1]. The Lancet. 349. 501–502. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bonnie J. Deroo Breakdown of academic impact, for papers by Stefano Bertolini Breakdown of academic impact, for papers by Giuseppe Pandini Breakdown of academic impact, for papers by Shixia Huang Breakdown of academic impact, for papers by Kimberly D. Kluckman Breakdown of academic impact, for papers by Hyun‐Seok Kim Breakdown of academic impact, for papers by Jackie A. Lavigne Breakdown of academic impact, for papers by Anders Ström Breakdown of academic impact, for papers by Lothar Rössig Breakdown of academic impact, for papers by Jack Youngren
Rankless by CCL
2026